Darzalex

• Darzalex is a monoclonal antibody therapy for multiple myeloma.
• It targets the CD38 protein on myeloma cells, leading to their destruction.
• Used alone or in combination, it significantly improves outcomes for patients.
• Common side effects include infusion-related reactions and fatigue.
• Regular monitoring and communication with healthcare providers are essential during treatment.

What is Darzalex?

Darzalex is a prescription medicine known scientifically as daratumumab. It is a type of biologic therapy, specifically a monoclonal antibody, designed to treat adults with multiple myeloma. This medication represents a significant advancement in oncology, providing a targeted approach to combating this complex blood cancer. The question of what is Darzalex used for is primarily answered by its role in treating multiple myeloma, either as a standalone therapy or in combination with other drugs.

The Darzalex mechanism of action involves targeting a specific protein called CD38, which is highly expressed on the surface of multiple myeloma cells. Once Darzalex binds to CD38, it triggers several immune responses that lead to the destruction of the cancer cells. These mechanisms include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). By selectively targeting CD38, Darzalex helps to eliminate myeloma cells while minimizing harm to healthy cells that do not express CD38 as prominently.

Darzalex Treatment for Multiple Myeloma

Darzalex treatment for multiple myeloma has become a cornerstone in managing this challenging disease. Multiple myeloma is a cancer of plasma cells, a type of white blood cell found in the bone marrow. According to the American Cancer Society, an estimated 35,730 new cases of multiple myeloma will be diagnosed in 2024 in the United States, highlighting the ongoing need for effective therapies like Darzalex. It is approved for use in various settings, including newly diagnosed patients and those with relapsed or refractory multiple myeloma who have not responded to previous treatments.

Darzalex is administered intravenously (into a vein) by a healthcare professional. The treatment schedule can vary depending on whether it is used as a monotherapy or in combination with other anti-myeloma agents, such as proteasome inhibitors or immunomodulatory drugs. Typically, patients receive infusions on a weekly basis initially, which may then transition to less frequent schedules. Due to the potential for infusion-related reactions, patients are closely monitored during and after their Darzalex infusions, and pre-medications are often given to help manage these reactions.

Understanding Darzalex Side Effects

Like all medications, Darzalex can cause side effects. Understanding Darzalex side effects is crucial for patients and their healthcare providers to manage treatment effectively. The most common side effects are infusion-related reactions, which can include symptoms such as chills, shortness of breath, cough, throat irritation, and nausea. These reactions typically occur during or within 24 hours of the first infusion but can also happen with subsequent doses.

Other common side effects may include:

• Fatigue
• Nausea and diarrhea
• Upper respiratory tract infections
• Cough
• Swelling in the hands or feet (peripheral edema)

More serious, though less common, side effects can include a decrease in blood cell counts (e.g., neutropenia, thrombocytopenia, anemia), which can increase the risk of infection or bleeding. Patients should report any new or worsening symptoms to their doctor immediately. Healthcare providers will monitor blood counts regularly and may adjust treatment or provide supportive care as needed to manage these potential adverse effects.